fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
| Descriptor ID |
D051941
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.630.020 D12.776.624.664.700.114
|
| Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigens
- Antigens, CD135
- CD135 Antigen
- Antigen, CD135
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in this website by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 7 | 7 |
| 2005 | 0 | 2 | 2 |
| 2006 | 4 | 1 | 5 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 8 | 10 |
| 2009 | 4 | 0 | 4 |
| 2010 | 3 | 5 | 8 |
| 2011 | 11 | 4 | 15 |
| 2012 | 7 | 5 | 12 |
| 2013 | 12 | 4 | 16 |
| 2014 | 7 | 2 | 9 |
| 2015 | 5 | 3 | 8 |
| 2016 | 6 | 5 | 11 |
| 2017 | 7 | 4 | 11 |
| 2018 | 6 | 7 | 13 |
| 2019 | 13 | 5 | 18 |
| 2020 | 6 | 6 | 12 |
| 2021 | 6 | 5 | 11 |
| 2022 | 3 | 12 | 15 |
| 2023 | 1 | 7 | 8 |
| 2024 | 5 | 3 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia. JAMA Oncol. 2024 Aug 01; 10(8):1104-1110.
-
Precision medicine in AML: overcoming resistance. Int J Hematol. 2024 Oct; 120(4):439-454.
-
Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Nov; 24(11):e819-e826.
-
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer. 2024 Oct 15; 130(20):3452-3462.
-
The multi-kinase inhibitor CG-806 exerts anti-cancer activity against acute myeloid leukemia by co-targeting FLT3, BTK, and aurora kinases. Leuk Lymphoma. 2024 Nov; 65(11):1659-1674.
-
Phase 1 study of azacitidine in combination with quizartinib in patients with FLT3 or CBL mutated MDS and MDS/MPN. Leuk Res. 2024 Jul; 142:107518.
-
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 May 01; 42(13):1499-1508.
-
Feasible diet and circadian interventions reduce in?vivo progression of FLT3-ITD-positive acute myeloid leukemia. Cancer Med. 2024 Jan; 13(2):e6949.
-
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 2024 01; 38(1):82-95.
-
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv. 2023 11 14; 7(21):6624-6629.